Plasma miR-145 as a novel biomarker for the diagnosis and radiosensitivity prediction of human cervical cancer

Hu Wei, Chen Wen-Ming and Jiao Jun-Bo

Abstract
Objectives: The objective of this study was to evaluate levels of plasma miR-145 in patients with cervical cancer (CC) and investigate its biomarker potential.
Methods: Using qRT-PCR, we compared plasma miR-145 levels in 120 patients with CC, 120 patients with cervical intraepithelial neoplasia (CIN), and 120 healthy volunteers. The association between plasma miR-145 expression and clinicopathological factors, including radiation response, was also analyzed.
Results: Plasma miR-145 levels were lower in CC patient than in CIN patients and healthy controls. Low levels were significantly associated with poor cancer differentiation, lymph node metastasis, HPV, and advanced FIGO stage. CC patients who achieved complete response to radiotherapy had higher plasma miR-145 levels than incomplete responders. ROC analysis confirmed that plasma miR-145 is a candidate biomarker for detecting CC and differentiating complete responders from incomplete responders.
Conclusions: Plasma miR-145 is reduced in CC and is a novel candidate biomarker for diagnosing CC and predicting radiosensitivity.

Keywords
MiR-145, plasma biomarker, cervical cancer, diagnosis

Date received: 27 February 2017; accepted: 21 April 2017

Introduction
Cervical cancer (CC) is the third most common female malignancy worldwide, with approximately 529,000 new cases and 274,000 deaths per year. Early diagnosis of CC is associated with favorable prognosis.
Many CC patients with early stage disease are successfully cured, but the 5-year survival rate for patients diagnosed at FIGO stage IV is as low as 15%. Radiotherapy, one of the main treatment options for CC, is used for over 60% of CC cases. For some early stage patients, radiotherapy is as effective as radical surgery. Unfortunately, CC is often diagnosed at an advanced clinical stage, and some patients with CC present with either intrinsic or acquired radioresistance, resulting in treatment failure and eventually poor outcome. New, effective, reliable, and noninvasive biomarkers for early detection and prediction of radiosensitivity prediction are still urgently needed.

MicroRNAs (miRs) are a class of small noncoding RNAs approximately 20 nucleotides long. MiRs can negatively regulate gene expression by binding to 3'-untranslated regions of target mRNAs. MiRs play important roles in multiple biological processes including cellular proliferation, differentiation, apoptosis, angiogenesis, invasion, and migration. In addition, some miRs may function as either oncogenes or tumor suppressors, and altered expression of miRs has been associated with tumor initiation and progression. Furthermore, miRs are present in plasma and serum, and blood miRs are protected from RNase digestions. These findings suggest that circulating miRs might serve as biomarkers for cancer diagnosis, prognosis, and treatment monitoring. For example, serum miR-21, miR-155, and miR-365 can be used for detection of breast cancer. Low level of serum miR-503 predicted poor overall survival in patients with gastric cancer. Serum miR-4772-3 p expression was associated with response to FOLFOX adjuvant chemotherapy and tumor recurrence in colon cancer patients.

One of the cancer-related miRs is miR-145. MiR-145 is downregulated in osteosarcoma, ovarian cancer, breast cancer, gastric cancer, hepatocellular carcinoma, lung cancer, and colorectal cancer. MiR-145 acts as a tumor suppressor gene in these tumors. Low levels of miR-145 in CC tissues are correlated with lymph node metastasis and advanced clinical stage. Overexpression of miR-145 may suppress CC cell proliferation and invasion and enhance radiosensitivity. Recent studies have found decreased blood miR-145 levels in patients with malignant bone tumors and ovarian cancer and have studied the clinical significance of these changes. However, plasma miR-145 expression and its potential diagnostic value in CC remains unknown. In the present study, we detected plasma miR-145 levels in CC patients and evaluated its association with clinical parameters. Furthermore, we explored whether plasma miR-145 could serve as a useful biomarker for CC diagnosis and prediction of radiosensitivity.

Materials and methods

Patients and samples

This study was approved by the ethics committee of Jining No.1 People’s Hospital (No 2010037) and written informed consent was obtained from each participant. A total of 120 patients were enrolled in the study. All patients had pathologically confirmed CC and were treated with radiotherapy at Jining No.1 People’s Hospital between January 2010 and September 2015. None of the patients had previously undergone chemotherapy, radiation therapy, or immunotherapy. The samples were collected in PAXgene blood RNA tubes (PreAnalytiX QIAGEN/BD) and centrifuged at 3000 rpm for 15 min at 4°C. The plasma was immediately frozen and stored at −80°C until use. Plasma samples from 120 cervical intraepithelial neoplasia (CIN) patients and 120 healthy
volunteers were used as controls. The clinical characteristics of CC patients were summarized in Table 1. These patients were classified into two groups according to the response to radiotherapy: a complete response group and an incomplete response group (including partial response, stable disease, and progressive response) as previously described.25,26

### MiR isolation and real-time RT-PCR

Total RNA was extracted from 400 µL of plasma samples using a miRVana PARIS Kit (Ambion, Austin, TX, USA). Reverse-transcription was carried out with the TaqMan microRNA Reverse Transcription Kit (Applied Biosystems, CA, USA). The reaction mixtures were incubated at 16°C for 30 min, followed by 42°C for 30 min, then 85°C for 5 min before being held at 4°C. Quantitative PCR was performed on an ABI7500 fast real-time PCR system (Applied Biosystems) in a final volume of 20 µL with the human TaqMan MicroRNA Assay Kit (Applied Biosystems). PCR cycling conditions included 50°C for 2 min and 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. The expression of miR-145 was normalized to RNU6B as previously described,27,28 and relative expression of miR-145 was calculated using the $2^{-\Delta\Delta Ct}$ method.29,30 The primer sequences used were: miR-145, 5’-AAG CTT CAG AGG GTT CCC GGT ACTT-3’ (forward) and 5’-CTC GAG AGC

### Table 1. Correlations of plasma miR-145 levels and clinical characteristics of cervical cancer patients. NS = not significant.

| Characteristics                        | Patients | miR-145 level | P value |
|----------------------------------------|----------|---------------|---------|
| Age (yr)                               |          |               |         |
| <50                                    | 59       | 0.34 ± 0.04   |         |
| ≥50                                    | 61       | 0.31 ± 0.03   | NS      |
| Histological grades                    |          |               |         |
| Well/Moderate                          | 64       | 0.41 ± 0.05   |         |
| Poor                                   | 56       | 0.26 ± 0.03   | 0.027   |
| Histological type                      |          |               |         |
| Adenocarcinoma                         | 19       | 0.30 ± 0.03   |         |
| Squamous cell carcinoma                | 101      | 0.35 ± 0.04   | NS      |
| Tumor size (cm)                        |          |               |         |
| <4                                     | 66       | 0.37 ± 0.04   |         |
| ≥4                                     | 54       | 0.29 ± 0.02   | NS      |
| Lymph node metastasis                  |          |               |         |
| Positive                               | 47       | 0.22 ± 0.03   |         |
| Negative                               | 73       | 0.45 ± 0.06   | 0.009   |
| FIGO stage                             |          |               |         |
| I–II                                   | 77       | 0.49 ± 0.06   |         |
| III                                    | 43       | 0.16 ± 0.02   | 0.002   |
| HPV infection                          |          |               |         |
| Positive                               | 81       | 0.25 ± 0.03   |         |
| Negative                               | 39       | 0.42 ± 0.05   | 0.016   |
| Tumor response                         |          |               |         |
| Complete responder                     | 68       | 0.47 ± 0.05   |         |
| Incomplete responder                   | 52       | 0.19 ± 0.02   | 0.005   |
CTC ACA GGG ATG TTA TG-3’ (reverse); RNU6B, 5’-CGC TTC GGC AGC ACA TAT AC-3’ (forward) and 5’-TTC ACG AAT TTG CGT GTC AT-3’ (reverse).

**Statistics**

All statistical calculations were performed using SPSS version 16.0 (SPSS Inc., Chicago, IL, USA), and P values below 0.05 were considered statistically significant. The differences in miR-145 expression were analyzed using a Mann-Whitney unpaired test. Receiver operating characteristic (ROC) curves and area under the ROC curve (AUC) were used to assess the diagnostic value of miR-145.

**Results**

**Decreased levels of plasma miR-145 in patients with CC**

The levels of plasma miR-145 in CC patients, CIN patients, and healthy volunteers were examined using qRT-PCR. Levels of miR-145 were significantly lower in plasma from patients with CC than in plasma from CIN patients and healthy controls (Figure 1; both P < 0.01). No significant difference was observed in the plasma miR-145 expression between CIN patients and healthy controls.

ROC curve analysis indicated that the plasma levels of miR–145 differentiated CC from healthy controls, with an AUC of 0.848 (95% CI: 0.802–0.894; sensitivity: 81.7%, specificity: 63.3%; Figure 2(a)). We also evaluated the diagnostic value of plasma miR-145 for differentiating CC patients from CIN patients. As shown in Figure 2(b), the AUC was 0.828 (95% CI: 0.779–0.878), with a sensitivity of 91.7% and specificity of 54.2%.

**Low level of plasma miR-145 correlates with CC progression and radioresistance**

We examined the association of plasma miR-145 level with clinicopathological characteristics of the 120 CC patients. Low plasma miR-145 level was significantly associated with poor cancer differentiation (P = 0.027), lymph node metastasis (P = 0.009), HPV infection (P = 0.016), and advanced FIGO stage (P = 0.002). In addition, the expression level of miR-145 was significantly higher in the plasma samples of the complete response group than in those of the incomplete response group (P = 0.005, Table 1). ROC curve analysis revealed that plasma miR-145 distinguished complete responders from incomplete responders with an AUC of 0.801 (95% CI: 0.724–0.878; sensitivity: 64.7%, specificity: 84.6%; Figure 2(c)).

**Discussion**

There is a growing body of evidence showing that miRs are stable in human body fluids and their expression levels may be clinically relevant. In this study, levels of miR-145 were lower in plasma from CC patients than
in plasma from CIN patients and healthy controls. Low plasma miR-145 expression was correlated with poor differentiation, lymph node metastasis, HPV infection, advanced clinical stage, and poor tumor response to radiotherapy. Moreover, plasma miR-145 level could differentiate CC from CIN and healthy controls and distinguish complete responders from incomplete responders. To our knowledge, this is the first study to investigate circulating miR-145 levels and explore the clinical significance of this biomarker in CC patients.

Decreased circulating miR-145 has been previously reported in patients with other malignancies. Gao et al. revealed that miR-145 expression in the plasma of patients with malignant bone tumors was significantly lower than in plasma of patients with benign bone tumors or healthy subjects. Liang et al. demonstrated that serum miR-145 is decreased in ovarian cancer patients and serum miR-145 level could be used to distinguish ovarian cancer patients from healthy controls. Low levels of serum miR-145 predicted poor overall survival. Thus, circulating miR-145 may be a useful marker for cancer diagnosis and prognosis, and the potential clinical significance of blood miR-145 in other cancers should be studied further.

The efficacy of radiation therapy is often limited by radioresistance. Reliable markers that can predict radiosensitivity before treatment begins are critically needed. MiR-145 can target the DNA damage repair-associated gene HLTF, which is involved in radioresistance, and ectopic expression of miR-145 significantly sensitized prostate cancer cells to radiation. Overexpression of

![Figure 2. ROC curve analysis of plasma miR-145 for discriminating (a) cervical cancer (n = 120) from healthy controls (n = 120), (b) cervical cancer from cervical intraepithelial neoplasia (n = 120), and (c) complete responders (n = 68) from incomplete responders (n = 52).](image-url)
miR-145 in CC cells enhanced radiosensitivity in vitro and in vivo. In our study, CC patients who achieved complete response to radiotherapy had higher plasma miR-145 levels than those who failed to achieve a complete response. ROC curve analysis confirmed that plasma miR-145 is a valuable biomarker for differentiating complete responders from incomplete responders. Therefore, plasma miR-145 is a candidate biomarker for prediction of radiosensitivity of cancers.

We are aware of some limitations in our work. First, this was a retrospective study. Second, our study investigated miR-145 only. Since miRs acts as a network rather than individually, clinical significance of other circulating miRs in CC should be evaluated.

In summary, this study showed that plasma miR-145 is decreased in CC and associated with aggressive clinicopathological features. More importantly, plasma miR-145 is a candidate biomarker for diagnosis of CC and prediction of radiosensitivity. Prospective studies with larger sample size should be conducted to confirm these conclusions.

Declaration of conflicting interest
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

References
1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893–2917.
2. Burki TK. Cervical cancer: screening and risk with age. Lancet Oncol 2014; 15: e107.
3. Rogers L, Siu SS, Luesley D, et al. Radiotherapy and chemoradiation after surgery for early cervical cancer. Cochrane Database Syst Rev 2012; CD007583.
4. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69–90.
5. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281–297.
6. Tufekci KU, Meuwissen RL and Genc S. The role of microRNAs in biological processes. Methods Mol Biol 2014; 1107: 15–31.
7. Wang S, Wu W and Claret FX. Mutual regulation of microRNAs and DNA methylation in human cancers. Epigenetics 2017; 12: 187–197.
8. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008; 105: 10513–10518.
9. Zhao Y, Song Y, Yao L, et al. Circulating microRNAs: promising biomarkers involved in several cancers and other diseases. DNA Cell Biol 2017; 36: 77–94.
10. Han JG, Jiang YD, Zhang CH, et al. A novel panel of serum miR-21/miR-155/miR-365 as a potential diagnostic biomarker for breast cancer. Ann Surg Treat Res 2017; 92: 55–66.
11. Wu D, Cao G, Huang Z, et al. Decreased miR-503 expression in gastric cancer is inversely correlated with serum carcinoembryonic antigen and acts as a potential prognostic and diagnostic biomarker. Onco Targets Ther 2017; 10: 129–135.
12. Liu C, Eng C, Shen J, et al. Serum exosomal miR-4772-3p is a predictor of tumor recurrence in stage II and III colon cancer. Oncotarget 2016; 7: 76250–76260.
13. Zhang Z, Zhang M, Chen Q, et al. Downregulation of microRNA-145 promotes epithelial-mesenchymal transition via regulating Snail in osteosarcoma. Cancer Gene Ther 2017; 24: 83–88.
14. Wu H, Xiao Z, Wang K, et al. MiR-145 is downregulated in human ovarian cancer and modulates cell growth and invasion by targeting p70S6K1 and MUC1. Biochem Biophys Res Commun 2013; 441: 693–700.
15. Zheng M, Sun X, Li Y, et al. MicroRNA-145 inhibits growth and migration of breast
cancer cells through targeting oncoprotein ROCK1. Tumour Biol 2016; 37: 8189–8196.
16. Chen JJ, Cai WY, Liu XW, et al. Reverse correlation between MicroRNA-145 and FSCN1 affecting gastric cancer migration and invasion. PLoS One 2015; 10: e0126890.
17. Gao F, Sun X, Wang L, et al. Downregulation of MicroRNA-145 caused by Hepatitis B Virus X Protein promotes expression of CUL5 and contributes to pathogenesis of Hepatitis B Virus-associated hepatocellular carcinoma. Cell Physiol Biochem 2015; 37: 1547–1559.
18. Ling DJ, Chen ZS, Zhang YD, et al. MicroRNA-145 inhibits lung cancer cell metastasis. Mol Med Rep 2015; 11: 3108–3114.
19. Qin J, Wang F, Jiang H, et al. MicroRNA-145 suppresses cell migration and invasion by targeting paxillin in human colorectal cancer cells. Int J Clin Exp Pathol 2015; 8: 1328–1340.
20. Wang Q, Qin J, Chen A, et al. Downregulation of microRNA-145 is associated with aggressive progression and poor prognosis in human cervical cancer. Tumour Biol 2015; 36: 3703–3708.
21. Ye C, Sun NX, Ma Y, et al. MicroRNA-145 contributes to enhancing radiosensitivity of cervical cancer cells. FEBS Lett 2015; 589: 702–709.
22. Sathyanarayanan A, Chandrasekaran KS and Karunagaran D. microRNA-145 modulates epithelial-mesenchymal transition and suppresses proliferation, migration and invasion by targeting SIP1 in human cervical cancer cells. Cell Oncol 2016; 40: 119–131.
23. Liang H, Jiang Z, Xie G, et al. Serum microRNA-145 as a novel biomarker in human ovarian cancer. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine 2015; 36: 5305–5313.
24. Gao F, Tian J, Liu XD, et al. MicroRNA-145 expression in the plasma of patients with benign and malignant bone tumors and its effects on osteosarcoma cell proliferation and migration. Panminerva Med 2016; 58: 103–108.
25. Liu S, Pan X, Yang Q, et al. MicroRNA-18a enhances the radiosensitivity of cervical cancer cells by promoting radiation-induced apoptosis. Oncol Rep 2015; 33: 2853–2862.
26. Hernowo BS, Suryanti S and Wibisono F. Correlation between EGFR expression and radiosensitivity in cervical adenocarcinoma cases. Asian Pac J Cancer Prev 2016; 17: 2535–2537.
27. Kachakova D, Mitkova A, Popov E, et al. Combinations of serum prostate-specific antigen and plasma expression levels of let-7c, miR-30c, miR-141, and miR-375 as potential better diagnostic biomarkers for prostate cancer. DNA Cell Biol 2015; 34: 189–200.
28. Liu P, Xin F and Ma CF. Clinical significance of serum miR-196a in cervical intraepithelial neoplasia and cervical cancer. Genet Mol Res 2015; 14: 17995–18002.
29. Jin C, Shi W, Wang F, et al. Long non-coding RNA HULC as a novel serum biomarker for diagnosis and prognosis prediction of gastric cancer. Oncotarget 2016; 7: 51763–51772.
30. Wu C, Li M, Hu C and Duan H. Clinical significance of serum miR-223, miR-25 and miR-375 in patients with esophageal squamous cell carcinoma. Mol Biol Rep 2014; 41: 1257–1266.
31. Gong P, Zhang T, He D, et al. MicroRNA-145 modulates tumor sensitivity to radiation in prostate cancer. Radiat Res 2015; 184: 630–638.
32. Volinia S, Galasso M, Costinean S, et al. Reprogramming of miRNA networks in cancer and leukemia. Genome Res 2010; 20: 589–599.